ACTA NEUROPATHOLOGICA, published by Springer, is a leading journal in the fields of cellular and molecular neuroscience, clinical neurology, and pathology, recognized for its exceptional quality and impactful research. With an impressive impact factor and currently ranked in the Q1 tier across multiple categories in 2023, this journal serves as a premier platform for the dissemination of groundbreaking findings in neuropathology. The journal's robust Scopus rankings highlight its influence, standing at #2 in Pathology and Forensic Medicine and #5 in Clinical Neurology. Since its inception in 1961, ACTA NEUROPATHOLOGICA has provided crucial insights into neurological diseases and disorders, contributing significantly to the advancement of medical science. Aimed at researchers, practitioners, and students alike, this journal fosters a deeper understanding of neurological conditions and encourages innovative approaches within the field. It is essential reading for anyone dedicated to unraveling the complexities of the nervous system.

Neurology-Neuroimmunology & Neuroinflammation, published by LIPPINCOTT WILLIAMS & WILKINS, stands at the forefront of research in the rapidly evolving fields of neurology and neuroimmunology. Since its inception in 2014, this prestigious journal has embraced an Open Access model, ensuring that groundbreaking findings are readily available to researchers, clinicians, and students worldwide. Covering a broad spectrum of topics related to neuroinflammation, the journal has gained a remarkable reputation, attaining a Q1 ranking in both Neurology and Neurology (clinical) as of 2023, and ranking #6 out of 192 in the neuroscience category on Scopus. The journal's commitment to high-quality research aims to facilitate the understanding of neurological disorders, promote innovative therapies, and inspire collaboration among professionals. Addressing critical issues at the intersection of neurology, immunology, and clinical practice, Neurology-Neuroimmunology & Neuroinflammation is an essential platform for the dissemination of knowledge and the advancement of this vital field.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

Frontiers in Molecular Neuroscience, published by FRONTIERS MEDIA SA, is an esteemed open-access journal dedicated to advancing our understanding of the molecular mechanisms underlying neurological functions and disorders. Since its inception in 2008, the journal has established itself as a reputable source of cutting-edge research, earning a respectable Q2 ranking in both the fields of Cellular and Molecular Neuroscience and Molecular Biology as of 2023. With an ongoing commitment to fostering innovation, the journal presents a platform for researchers, professionals, and students to disseminate their findings and engage in scholarly discourse. The E-ISSN 1662-5099 ensures that research is readily accessible, facilitating the exchange of knowledge crucial to tackling the complexities of neurological conditions. Situated in Switzerland, the journal’s global reach is augmented by its open-access model, allowing for wide dissemination of critical research findings to a diverse audience. Join the vibrant community of scientists and practitioners who are shaping the future of molecular neuroscience through their contributions to this dynamic journal.

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

BIOCHEMICAL PHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, stands as a leading international journal devoted to the advancing field of biochemical pharmacology. Since its inception in 1958, the journal has continuously offered a platform for innovative research, delivering critical insights into the interaction between biochemical processes and pharmaceutical applications, and now converges towards its 2024 edition. With an impressive Q1 ranking in both Biochemistry and Pharmacology categories, it ranks 32nd out of 313 in Pharmacology and Toxicology, and 58th out of 438 in Biochemistry according to Scopus, showcasing its significant impact within the scientific community. Researchers and professionals rely on this journal to keep abreast of essential developments, given its robust peer-review process and a comprehensive selection of articles that span experimental studies, clinical trials, and theoretical analyses. Although not an Open Access journal, it remains pivotal for those seeking to advance their knowledge in the dynamic fields of biochemistry and pharmacology. With its high impact factor and emphasis on quality research, BIOCHEMICAL PHARMACOLOGY continues to be an invaluable resource for students, researchers, and industry professionals striving to make breakthroughs in drug development and therapeutic strategies.

NEUROLOGICAL RESEARCH, published by TAYLOR & FRANCIS LTD, is a distinguished journal focusing on the diverse and evolving field of neurology. Established in 1979, this journal has been a prominent platform for disseminating groundbreaking research and clinical advances up to 2024. With an ISSN of 0161-6412 and an E-ISSN of 1743-1328, it offers valuable insights for researchers, professionals, and students interested in the intricate workings of the nervous system. The journal holds a respectable Q2 ranking in the field of Medicine (miscellaneous) and Q3 in the categories of Neurology and Clinical Neurology, reflecting its commitment to high-quality research. Although NEUROLOGICAL RESEARCH does not currently offer an open access option, its contributions to the literature are vital for fostering advancements in neurological understanding and treatment. With an engaged readership and a mission to advance scientific knowledge, NEUROLOGICAL RESEARCH serves as a crucial resource for anyone dedicated to neurological health and innovation.

ACS Chemical Neuroscience, published by the American Chemical Society, is a premier journal dedicated to exploring the complex interactions between chemistry and neuroscience. With its ISSN 1948-7193 and a distinguished impact factor that positions it within the top quartiles across multiple categories, including Q1 in Biochemistry, Q2 in Cell Biology, and Q1 in Physiology, this journal serves as an essential platform for researchers engaged in cutting-edge studies from 2010 to 2024. Positioned within the top 15% of its field in Cognitive Neuroscience according to Scopus rankings, ACS Chemical Neuroscience strives to foster interdisciplinary collaboration, publishing significant advancements that integrate chemical concepts with neurological processes. Despite its traditional publication model, the journal is committed to maintaining rigorous peer-review standards and providing valuable insights that drive innovations in therapeutics and understanding the biochemical underpinnings of brain function. Researchers, professionals, and students alike will find in this journal a vital resource for the latest findings and methodologies in the dynamic intersection of chemistry and neuroscience.